Key Takeaways
- Guggenheim elevated Spyre Therapeutics to its premier biotech selection following encouraging Phase II results for SPY003 in ulcerative colitis treatment
- The SKYLINE-UC trial demonstrated 20% clinical remission and 30% endoscopic remission with SPY003
- Baird maintained its Outperform rating with a $116 price objective; Guggenheim maintains a $130 target
- SYRE has surged 442% since the beginning of the year, currently trading near $90.79
- Critical data from the expanded SKYLINE Part B combination trial is anticipated in 2027
Shares of Spyre Therapeutics (SYRE) advanced more than 2% during Wednesday’s session, reaching approximately $90.79, following Guggenheim’s announcement designating it as the firm’s premier biotech selection after the company released Phase II clinical trial data for SPY003, its ulcerative colitis drug candidate.
Spyre Therapeutics, Inc., SYRE
The clinical study, designated as SKYLINE-UC, assessed SPY003 as a single-agent therapy across three treatment groups encompassing a total of 135 participants. SPY003 represents an extended-duration anti-IL-23 monoclonal antibody therapeutic.
The findings revealed 20% clinical remission rates, 30% endoscopic remission rates, and a negative 10.0 shift in the Robarts Histopathology Index. According to Guggenheim, these outcomes align with existing IL-23p19 comparator medications currently available in the marketplace.
Approximately 41% of trial participants were categorized as advanced therapy-experienced, indicating that a substantial portion had previously attempted and failed to respond to alternative treatments, including JAK inhibitors and IL-12/23 therapeutic agents. The safety evaluation returned favorable results, showing zero drug-related serious adverse events and no participant withdrawals attributable to adverse events.
Guggenheim emphasized durability as SPY003’s principal competitive advantage, characterizing it as a promising candidate for combination therapy applications beyond standalone treatment use.
Wall Street Analyst Perspectives
Baird also reaffirmed its Outperform rating on Wednesday, maintaining its $116 price objective. The investment firm indicated that the SPY003 outcomes were anticipated given the well-documented mechanism of action, though characterized them as incrementally encouraging.
Baird emphasized that the IL-23 inhibitory pathway has already received validation through other authorized medications. The firm’s attention now centers on subsequent developments: the expanded, placebo-controlled SKYLINE Part B investigation.
Guggenheim reaffirmed its Buy recommendation with a $130 price objective. Stifel likewise maintained its Buy rating with a $123 target. Mizuho increased its price target to $120, referencing SPY120’s potential to deliver robust clinical remission outcomes.
However, sentiment isn’t universally optimistic. Wolfe Research downgraded SYRE to Peerperform from Outperform, expressing reservations regarding the assessment of recent data and expressing limited confidence in forthcoming catalysts.
Future Developments on the Horizon
The conclusion of Phase II Part A now paves the way for Part B, which is currently enrolling participants. This investigation will examine two dosage levels for each monotherapy along with three high-dose combination therapy groups, targeting the α4β7, TL1A, and IL-23 pathways simultaneously.
Top-line induction results from Part B are projected for 2027. Baird indicated this represents the timeframe when the most significant data supporting the company’s fundamental investment thesis will emerge.
An additional near-term catalyst warrants attention. Spyre’s SPY072 SKYWAY-RD data release in psoriatic arthritis and axial spondyloarthritis is anticipated during Q4 2026.
On a cautionary note, Spyre recently disclosed that SPY072 in a rheumatoid arthritis sub-investigation failed to achieve its internal benchmark for monotherapy advancement, despite demonstrating statistically significant improvements compared to placebo. This outcome triggered the Wolfe Research downgrade.
Wall Street’s consensus rating remains a strong buy, with price objectives spanning from $97 to $130. SYRE has appreciated 442% year-to-date.
The post Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results appeared first on Blockonomi.
